116 related articles for article (PubMed ID: 38760788)
1. Analysis of CD20 and PD-L1 levels on small extracellular vesicles (sEV) produced by DLBCL cells and EBV-transformed B cells, and potential role in T cell inhibition.
Akil H; Bentayeb H; Aitamer M; Vignoles C; Abraham J; Gachard N; Olivrie A; Guyot A; Gobbo J; Feuillard J; Shirvani H; Troutaud D
Exp Hematol Oncol; 2024 May; 13(1):53. PubMed ID: 38760788
[TBL] [Abstract][Full Text] [Related]
2. CD20 expression, TrkB activation and functional activity of diffuse large B cell lymphoma-derived small extracellular vesicles.
Aitamer M; Akil H; Vignoles C; Branchaud M; Abraham J; Gachard N; Feuillard J; Jauberteau MO; Shirvani H; Troutaud D; Bentayeb H
Br J Cancer; 2021 Dec; 125(12):1687-1698. PubMed ID: 34743199
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic Performance of PD-L1 versus PD-1 Expression in Circulating CD20 Cells in Diffuse Large B-Cell Lymphoma.
Saber MM
Antibodies (Basel); 2022 Feb; 11(1):. PubMed ID: 35225873
[TBL] [Abstract][Full Text] [Related]
4. MiR155 sensitized B-lymphoma cells to anti-PD-L1 antibody via PD-1/PD-L1-mediated lymphoma cell interaction with CD8+T cells.
Zheng Z; Sun R; Zhao HJ; Fu D; Zhong HJ; Weng XQ; Qu B; Zhao Y; Wang L; Zhao WL
Mol Cancer; 2019 Mar; 18(1):54. PubMed ID: 30925928
[TBL] [Abstract][Full Text] [Related]
5. Universal extracellular vesicles and PD-L1+ extracellular vesicles detected by single molecule array technology as circulating biomarkers for diffuse large B cell lymphoma.
Li JW; Shi D; Wan XC; Hu J; Su YF; Zeng YP; Hu ZJ; Yu BH; Zhang QL; Wei P; Zhou XY
Oncoimmunology; 2021; 10(1):1995166. PubMed ID: 34745768
[TBL] [Abstract][Full Text] [Related]
6. Prognostic and clinicopathological significance of PD-1/PD-L1 expression in the tumor microenvironment and neoplastic cells for lymphoma.
Xie M; Huang X; Ye X; Qian W
Int Immunopharmacol; 2019 Dec; 77():105999. PubMed ID: 31704289
[TBL] [Abstract][Full Text] [Related]
7. Temsirolimus Enhances Anti-Cancer Immunity by Inducing Autophagy-Mediated Degradation of the Secretion of Small Extracellular Vesicle PD-L1.
Park SS; Kim JI; Lee CH; Bae JH; Park JM; Choe EJ; Baek MC
Cancers (Basel); 2022 Aug; 14(17):. PubMed ID: 36077620
[TBL] [Abstract][Full Text] [Related]
8. Frequent expression of PD-L1 in BLS-type diffuse large B-cell lymphoma: implications for aggressiveness and immunotherapy.
Yang CF; Yu YT; Wang SH; Chen YP; Chen TY; Hsu CY; Medeiros LJ; Chang KC
Pathology; 2024 Apr; 56(3):367-373. PubMed ID: 38290893
[TBL] [Abstract][Full Text] [Related]
9. Epstein-Barr virus-positive diffuse large B-cell lymphoma features disrupted antigen capture/presentation and hijacked T-cell suppression.
Jiang XN; Yu BH; Yan WH; Lee J; Zhou XY; Li XQ
Oncoimmunology; 2020; 9(1):1683346. PubMed ID: 32002294
[No Abstract] [Full Text] [Related]
10. Programmed cell death-ligand 1 (PD-L1)
Kimura S; Oshiro Y; Iwasaki H; Kadowaki M; Mihashi Y; Sakata T; Kawauchi S; Wang Z; Takamatsu Y; Takeshita M
Clin Exp Med; 2022 Aug; 22(3):411-419. PubMed ID: 34515880
[TBL] [Abstract][Full Text] [Related]
11. Immunosuppressive effect of small extracellular vesicle PD-L1 is restricted by co-expression of CD80.
Liu JY; Yu ZL; Fu QY; Zhang LZ; Li JB; Wu M; Liu B; Chen G
Br J Cancer; 2023 Oct; 129(6):925-934. PubMed ID: 37532831
[TBL] [Abstract][Full Text] [Related]
12. WJMSC-derived small extracellular vesicle enhance T cell suppression through PD-L1.
Li M; Soder R; Abhyankar S; Abdelhakim H; Braun MW; Trinidad CV; Pathak HB; Pessetto Z; Deighan C; Ganguly S; Dawn B; McGuirk J; Dunavin N; Godwin AK
J Extracell Vesicles; 2021 Feb; 10(4):e12067. PubMed ID: 33598108
[TBL] [Abstract][Full Text] [Related]
13. Oncolytic virus oHSV2 combined with PD-1/PD-L1 inhibitors exert antitumor activity by mediating CD4 + T and CD8 + T cell infiltration in the lymphoma tumor microenvironment.
Zhang J; Guo Y; Fang H; Guo X; Zhao L
Autoimmunity; 2023 Dec; 56(1):2259126. PubMed ID: 37736847
[TBL] [Abstract][Full Text] [Related]
14. Anti-Proliferative and Pro-Apoptotic vLMW Fucoidan Formulas Decrease PD-L1 Surface Expression in EBV Latency III and DLBCL Tumoral B-Cells by Decreasing Actin Network.
Saliba J; Manseur C; Groult H; Akil H; Tannoury M; Troutaud D; Maugard T; Feuillard J; Arnaudin I; Jayat-Vignoles C
Mar Drugs; 2023 Feb; 21(2):. PubMed ID: 36827173
[TBL] [Abstract][Full Text] [Related]
15. Genetic characteristics involving the PD-1/PD-L1/L2 and CD73/A2aR axes and the immunosuppressive microenvironment in DLBCL.
Zhang T; Liu H; Jiao L; Zhang Z; He J; Li L; Qiu L; Qian Z; Zhou S; Gong W; Meng B; Ren X; Zhang H; Wang X
J Immunother Cancer; 2022 Apr; 10(4):. PubMed ID: 35365585
[TBL] [Abstract][Full Text] [Related]
16. Immune Profiling and Quantitative Analysis Decipher the Clinical Role of Immune-Checkpoint Expression in the Tumor Immune Microenvironment of DLBCL.
Xu-Monette ZY; Xiao M; Au Q; Padmanabhan R; Xu B; Hoe N; Rodríguez-Perales S; Torres-Ruiz R; Manyam GC; Visco C; Miao Y; Tan X; Zhang H; Tzankov A; Wang J; Dybkær K; Tam W; You H; Bhagat G; Hsi ED; Ponzoni M; Ferreri AJM; Møller MB; Piris MA; van Krieken JH; Winter JN; Westin JR; Pham LV; Medeiros LJ; Rassidakis GZ; Li Y; Freeman GJ; Young KH
Cancer Immunol Res; 2019 Apr; 7(4):644-657. PubMed ID: 30745366
[TBL] [Abstract][Full Text] [Related]
17. Immunoglobulin somatic hypermutation has clinical impact in DLBCL and potential implications for immune checkpoint blockade and neoantigen-based immunotherapies.
Xu-Monette ZY; Li J; Xia Y; Crossley B; Bremel RD; Miao Y; Xiao M; Snyder T; Manyam GC; Tan X; Zhang H; Visco C; Tzankov A; Dybkaer K; Bhagat G; Tam W; You H; Hsi ED; van Krieken JH; Huh J; Ponzoni M; Ferreri AJM; Møller MB; Piris MA; Winter JN; Medeiros JT; Xu B; Li Y; Kirsch I; Young KH
J Immunother Cancer; 2019 Oct; 7(1):272. PubMed ID: 31640780
[TBL] [Abstract][Full Text] [Related]
18. Small extracellular vesicle PD-L1 in cancer: the knowns and unknowns.
Yu ZL; Liu JY; Chen G
NPJ Precis Oncol; 2022 Jun; 6(1):42. PubMed ID: 35729210
[TBL] [Abstract][Full Text] [Related]
19. Small Extracellular Vesicles in Pre-Therapy Plasma Predict Clinical Outcome in Non-Small-Cell Lung Cancer Patients.
Vetsika EK; Sharma P; Samaras I; Markou A; Georgoulias V; Whiteside TL; Kotsakis A
Cancers (Basel); 2021 Apr; 13(9):. PubMed ID: 33922569
[TBL] [Abstract][Full Text] [Related]
20. LncRNA MALAT1 promotes tumorigenesis and immune escape of diffuse large B cell lymphoma by sponging miR-195.
Wang QM; Lian GY; Song Y; Huang YF; Gong Y
Life Sci; 2019 Aug; 231():116335. PubMed ID: 30898647
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
